Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39244 Vincerx Pharma, Inc. (Exact name of Registrant as Specified in Its Charter) (Registrant's telephone numb ...

Core Points - Vincerx Pharma, Inc. intends to file a Form 25 Notification of Delisting with the SEC, which will remove its common stock from Nasdaq [1][3] - Nasdaq issued a Delisting Notice to Vincerx due to non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive business days [2] - The company's board has decided to dissolve and liquidate its business, distributing remaining assets to stockholders after settling debts [3] Summary by Sections Delisting and Trading Suspension - Vincerx's common stock will be permanently suspended from trading by Nasdaq at the opening of business on April 23, 2025, following a temporary suspension on April 16, 2025 [1][4] - The company is not eligible for a compliance period and will not appeal Nasdaq's determination [2][3] Company Actions - Vincerx plans to file a Form 25 to delist and deregister its common stock, followed by a Form 15 with the SEC once the delisting becomes effective [3][4] - The company does not intend to seek listing on another national securities exchange [3] Company Background - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, with a research facility in Monheim, Germany [5]

Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (“SEC”) on or about April 28, 2025, which will remove Vincerx’s common stock from listing and regi ...

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company’s board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. “I want to express our deepe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 83-3197402 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 1825 S. Grant Street San Mateo, CA 94402 For the transit ...

SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a rever ...

Core Viewpoint - Vincerx Pharma, Inc. has terminated its previously signed binding Term Sheet for a reverse merger transaction with Oqory, Inc. and Vivasor, Inc. [1] Group 1: Strategic Alternatives - The board of directors will reassess the Company's strategic alternatives, which may include out-licensing, merger and acquisition opportunities (including reverse mergers), sale of assets and technologies, and winding down operations [2] - The Company had approximately $3.9 million in cash as of February 26, 2025, with an expected cash runway extending through late Q2 2025 [2]

Core Insights - Vincerx Pharma and Oqory are highlighting the promising Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, and discussing their proposed strategic merger to advance this asset into global Phase 3 trials [1][5] Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a pipeline that includes next-generation ADCs and other innovative treatments [11] - Oqory, Inc. specializes in developing next-generation antibody drug conjugates (ADCs) for cancer treatment and has multiple ADC programs in clinical and preclinical stages [9] Clinical Data - OQY-3258 has shown promising results in clinical trials, including a 41% overall response rate (ORR) in patients with brain metastases and a progression-free survival (PFS) of 4.6 months compared to 2.8 months for historical data with Trodelvy [2][8] - In a Phase 3 study for unresectable recurrent or metastatic triple-negative breast cancer, OQY-3258 achieved an overall response rate of 80% in evaluable patients [4] Proposed Merger Details - The proposed merger will result in Oqory equity holders owning approximately 95% of the combined entity, with a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing [6] - The merger is contingent upon several conditions, including a concurrent private offering of at least $20 million in Vincerx equity securities and satisfactory completion of due diligence [6] Safety Profile - OQY-3258 has demonstrated a favorable safety profile, with manageable hematologic toxicities being the most common adverse events, and no Grade ≥3 rash or interstitial lung disease observed [2][8]

Core Insights - Vincerx Pharma, Inc. and Oqory, Inc. are collaborating to advance OQY-3258, an anti-TROP2 antibody-drug conjugate (ADC) for cancer treatment, and are proposing a strategic merger to enhance their ADC pipeline and expedite global Phase 3 trials [1][3][5] Company Overview - Vincerx Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, with a pipeline that includes next-generation ADCs and small molecule drug conjugates [10] - Oqory, Inc. specializes in developing next-generation ADCs and has multiple programs in clinical and preclinical stages targeting various cancers [8] Clinical Development - OQY-3258 is currently in Phase 1a/1b trials, having enrolled approximately 150 patients, with promising results particularly in breast cancer subtypes [2][7] - The ADC has shown a 41% overall response rate (ORR) in patients with brain metastases, outperforming historical data for similar treatments [2] - OQY-3258 has a favorable safety profile, with manageable hematologic toxicities and no severe off-target effects observed [2][7] Merger Details - The proposed merger will result in Oqory equity holders owning approximately 95% of the combined entity, with Vincerx equity holders retaining about 5% [5] - The merger is contingent upon several conditions, including a minimum financing of $20 million and satisfactory completion of due diligence [5][6] Future Prospects - The merger aims to accelerate the development of OQY-3258 and build a robust pipeline of next-generation ADCs to address significant unmet medical needs in cancer treatment [3][5]

Core Viewpoint - Vincerx Pharma, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective January 27, 2025, to reduce the number of issued shares and potentially enhance the stock price [1][2]. Summary by Sections Reverse Stock Split Details - The reverse stock split will convert every 20 issued shares into 1 issued share, reducing the total from approximately 44.8 million shares to about 2.2 million shares [2]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment instead [2]. - Adjustments will be made to the number of shares underlying outstanding equity awards, warrants, and other agreements [2]. Implementation and Process - Continental Stock Transfer & Trust Company will act as the exchange agent for the reverse stock split [3]. - Registered stockholders will have their positions automatically adjusted, while those with certificate shares will receive instructions from the exchange agent [3]. Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer [5]. - The company's pipeline includes several products in various stages of development, such as VIP943 in Phase 1 and VIP236, which has completed Phase 1 [5]. - Vincerx is headquartered in San Mateo, California, with a research facility in Monheim, Germany [6].